Table 2 |
|
|
Patient characteristics: metastatic disease |
|
| Characteristic |
n (%) |
|
|
|
| Menopausal status |
|
|
|
|
| Premenopausal |
5 (31) |
|
|
|
| Postmenopausal |
9 (56) |
|
|
|
| Unknown |
2 (13) |
|
|
|
| Disease sites |
|
|
|
|
| 1 |
1 (6) |
|
|
|
| 2 |
7 (44) |
|
|
|
| 3 |
6 (38) |
|
|
|
| ≥ 4 |
2 (12) |
|
|
|
| Predominantly visceral disease |
|
|
|
|
| Yes |
3 (19) |
|
|
|
| No |
13 (81) |
|
|
|
| Line of treatment |
|
|
|
|
| 0 |
3 (19) |
|
|
|
| 1 |
6 (37) |
|
|
|
| 2 |
3 (19) |
|
|
|
| ≥- 3 |
4 (25) |
|
|
|
| ER/PR tumor status |
|
|
|
|
| Positive |
11 (69) |
|
|
|
| Negative |
5 (31) |
|
|
|
| HER2 tumor status |
|
|
|
|
| Positivea |
5 (31) |
|
|
|
| Negative |
11(69) |
|
|
|
| EGFR tumor status |
|
|
|
|
| Positive |
1(6) |
|
|
|
| Negative |
9 (56) |
|
|
|
| Unknown |
6 (38) |
|
|
|
|
aA score +3 or fluorescence in situ hybridization positive. EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone receptor. |
|
|
Kallergi et al. Breast Cancer Research 2008 10:R80 doi:10.1186/bcr2149 |
|
